The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapy following definitive treatment in patients with stage I-III adenocarcinoma of the lung with G12C, G12D, or G12V KRAS mutations.
S. P. D'Angelo
No relevant relationships to disclose
B. J. Park
No relevant relationships to disclose
L. M. Krug
No relevant relationships to disclose
C. Crevar
No relevant relationships to disclose
C. E. Medina
No relevant relationships to disclose
D. K. Sumner
No relevant relationships to disclose
J. Richman
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
C. Coeshott
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
D. Apelian
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
A. Cohn
Employment or Leadership Position - GlobeImmune
Stock Ownership - GlobeImmune
M. G. Kris
No relevant relationships to disclose
C. G. Azzoli
No relevant relationships to disclose